Welcome to our dedicated page for Cognex SEC filings (Ticker: CGNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cognex Corporation (CGNX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing a structured view of how this industrial machine vision issuer reports its financial and corporate information. Cognex is incorporated in Massachusetts and files under Commission File Number 001-34218, with its common stock listed on NASDAQ under the symbol CGNX.
Among the key documents available are Form 10-K annual reports and Form 10-Q quarterly reports, where Cognex discusses its machine vision business, risk factors, and financial statements. These filings are important for understanding trends in logistics and factory automation demand, as well as the company’s investment in AI-enabled vision products, as referenced in its public communications.
Investors will also find Form 8-K current reports that Cognex uses to announce material events. Recent 8-K filings include the release of quarterly financial results, dividend declarations, and an audit firm rotation in which the Audit Committee selected KPMG LLP as the independent registered public accounting firm for a future fiscal year, following Grant Thornton LLP. Such filings provide timely insight into corporate actions and governance decisions.
On this page, users can monitor real-time updates from EDGAR, including 8-Ks, 10-Qs, 10-Ks, and other forms that Cognex may file. Stock Titan’s tools offer AI-powered summaries that help explain the contents of lengthy filings, highlight key sections, and clarify technical language around accounting, risk disclosures, and strategic priorities. In addition, Form 4 insider transaction reports, when filed, can be accessed to review share transactions by Cognex officers, directors, or significant shareholders.
By using the CGNX filings page, investors and researchers can quickly move from raw SEC documents to clearer explanations of how Cognex presents its financial condition, machine vision strategy, and corporate developments in official filings.
The Vanguard Group files an amendment stating it holds 0 shares (0%) of Cognex Corp common stock. The filing notes an internal realignment effective January 12, 2026 that caused certain Vanguard subsidiaries to report holdings separately. The statement is signed by Ashley Grim, Head of Global Fund Administration on 03/26/2026.
COGNEX CORP director Christopher Donato filed an initial Form 3, which records his status as a reporting insider of the company. The filing reports no purchases, sales, or other transactions in Cognex stock, serving only as a baseline disclosure of his insider position.
COGNEX CORP director Sami Atiya filed an initial insider ownership report on the company’s stock. The filing is a Form 3, which establishes Atiya’s status as a director and provides a baseline disclosure of insider holdings. It reports no purchases, sales, exercises, gifts, or other transactions.
Cognex Corp VP and principal accounting officer Laura Ann MacDonald reported routine equity compensation activity. On March 15, 2026 she exercised 368 restricted stock units, receiving an equal number of common shares. Of these, 109 shares were automatically withheld at a price of $47.98 per share to cover tax obligations, leaving her with 7,470 common shares held directly after the transactions. Each restricted stock unit represents a right to one Cognex common share, and the grant vests approximately 20%, 30%, and 50% on the first, second, and third anniversaries of the March 15, 2024 grant date.
Cognex Corporation is calling its 2026 annual shareholder meeting for April 29, 2026 at its Natick, Massachusetts headquarters. Shareholders of record on February 27, 2026, when 167,013,856 common shares were outstanding, may vote in person or by proxy.
Investors will vote on four proposals: electing three directors (Matthew Moschner, Angelos Papadimitriou, and Christopher Donato), approving an amendment to the 2023 Stock Option and Incentive Plan, ratifying the independent auditor, and an advisory say‑on‑pay resolution. The board recommends voting FOR all proposals.
The proxy details Cognex’s governance structure, board independence and committees, and a pay‑for‑performance philosophy emphasizing equity. In 2025, revenue grew 9%, operating margin improved from 12.6% to 16.3%, and the company returned $206 million to shareholders via dividends and buybacks, while tightening costs and revising executive bonus and PRSU designs for 2026.
Cognex director Dianne M. Parrotte exercised multiple non-qualified stock options on March 2, 2026 and immediately sold the resulting shares. She acquired 44,000 shares of Cognex common stock through option exercises at strike prices around $45–$51.49, then sold 44,000 shares in open-market transactions at $54.00 per share. After these transactions, she directly owned 33,431 Cognex common shares.
Cognex Corp director Dianne M. Parrotte increased her direct ownership through an equity award event. On February 21, 2026, she exercised or converted 2,913 Restricted Stock Units into 2,913 shares of Cognex common stock at a stated price of $0.0000 per share, indicating no cash outlay in this transaction. Following the conversion, her directly held common stock position rose to 33,431 shares. The filing also reports outstanding Non-Qualified Stock Options with direct ownership covering 7,500, 18,400, and 18,100 shares, which remain as rights to buy stock.
Cognex Corp director Angelos Papadimitriou reported a mix of stock transactions. On February 23, 2026, he sold 4,150 shares of common stock in an open-market transaction at an average price of $55.5804 per share, leaving 16,222 common shares directly owned.
On February 21, 2026, restricted stock units covering 2,537 shares were exercised and converted into the same number of common shares at no cash exercise price, increasing his common stock before the sale to 20,372 shares. Following these transactions, he also directly holds 4,817 restricted stock units that vest over time under a prior grant.